Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Travoprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR known ✓ | P43088 | 14/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.64 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Travoprost SCHEMBL93818 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL10015920 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL11907120 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL2177084 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL10086843 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL15074545 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL20485616 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL20485617 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL20664855 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Travoprost SCHEMBL1951740 | 1.00 | PTGFR (1.00) | PTGFRABCC4ABCB11PTGER3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285188-A1 | GLAUCOMA TREATMENT VIA INTRACAMERAL OCULAR IMPLANTS | ALLERGAN INC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11324757-B2 | Pharmaceutical composition for treatment of increased intraocular pressure | NOVALIQ GMBH (DE) | 2022-05-10 | — | — | US | disclosed |
| US-11254786-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | VANDERBILT UNIVERSITY (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3861982-A2 | INTRACAMERAL IMPLANT FOR TREATMENT OF AN OCULAR CONDITION | ALLERGAN, INC. (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210228408-A1 | Glaucoma Treatment Via Intracameral Ocular Implants | ALLERGAN INC (US) | 2021-07-29 | — | — | US | disclosed |
| EP-3076948-B1 | INTRACAMERAL IMPLANT FOR TREATMENT OF AN OCULAR CONDITION | ALLERGAN INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200206241-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INCREASED INTRAOCULAR PRESSURE | NOVALIQ GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
| US-10555953-B2 | Pharmaceutical composition for treatment of increased intraocular pressure | NOVALIQ GMBH (DE) | 2020-02-11 | — | — | US | disclosed |
| US-10442890-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | VANDERBILT UNIVERSITY (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190240234-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INCREASED INTRAOCULAR PRESSURE | NOVALIQ GMBH (DE) | 2019-08-08 | — | — | US | disclosed |
| EP-3076948-A1 | INTRACAMERAL IMPLANT FOR TREATMENT OF AN OCULAR CONDITION | Envisia Therapeutics Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160237208-A1 | Multifunctional Degradable Nanoparticles with Control over Size and Functionalities | UNIV VANDERBILT (US) | 2016-08-18 | — | — | US | disclosed |
| EP-2547323-B1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INCREASED INTRAOCULAR PRESSURE | NOVALIQ GMBH (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-20150157642-A1 | COSMETIC METHOD FOR CHANGING THE APPEARANCE OF EYES | TANG GORDON C (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2015085251-A1 | INTRACAMERAL IMPLANT FOR TREATMENT OF AN OCULAR CONDITION | ENVISIA THERAPEUTICS INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20140303166-A1 | COSMETIC METHOD FOR CHANGING THE APPEARANCE OF EYES | TANG GORDON C (US) | 2014-10-09 | — | — | US | disclosed |
| US-20130142733-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | VANDERBILT UNIVERSITY (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130046014-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INCREASED INTRAOCULAR PRESSURE | NOVALIQ GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-20130035338-A1 | EYELID TREATMENT | TANG GORDON (US) | 2013-02-07 | — | — | US | disclosed |
| WO-2011082432-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | VANDERBILT UNIVERSITY (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254786-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | DSTN, PARN, CTSA | PTGFR 2947/4885ABCC4 2635/4885ABCB11 950/4885 |
| US-10442890-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | DSTN, PARN, CTSA | PTGFR 2947/4885ABCC4 2635/4885ABCB11 950/4885 |
| US-20230285188-A1 | GLAUCOMA TREATMENT VIA INTRACAMERAL OCULAR IMPLANTS | PTGIR, PTGIS, PDE6A | PTGFR 21/4885ABCC4 1045/4885ABCB11 656/4885 |
| US-20210228408-A1 | Glaucoma Treatment Via Intracameral Ocular Implants | PTGIR, PTGIS, PDE6A | PTGFR 18/4885ABCC4 1043/4885ABCB11 662/4885 |
| US-20130142733-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | DSTN, PARN, CTSA | PTGFR 2947/4885ABCC4 2635/4885ABCB11 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.